Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus LOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus LOGEN.
AMARYL vs LOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
LOGEN (lofepramine) is a tricyclic antidepressant that primarily inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin at the presynaptic nerve terminal, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha1-adrenergic blocking properties.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
1-2 tablets (5-10 mg loperamide) orally after first loose stool, then 1 tablet (5 mg) after each subsequent loose stool; maximum 8 tablets (40 mg) per day for acute diarrhea; 4-8 tablets (20-40 mg) daily in divided doses for chronic diarrhea.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Terminal half-life is 2-4 hours in adults with normal renal function; extends to 8-12 hours in renal impairment. Clinical context: requires frequent dosing or renal dose adjustment.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Renal excretion dominates: 70-80% of the dose is eliminated unchanged in urine; biliary/fecal excretion accounts for 10-15%. Minimal hepatic metabolism.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic